Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB Therapeutics_resized
IRLAB Therapeutics (OMX: IRLAB-A) receives US$2.5m milestone payment
Published by Arron Aatkar, PhD

IRLAB Therapeutics has received a US$2.5m milestone payment from the McQuade Center for Strategic Research and Development for dosing the first patient in a new Phase I trial with IRL757. This is the second clinical study for the candidate (the first is supported by The Michael J. Fox Foundation), and is focused on assessing the pharmacokinetics, safety and tolerability of single ascending oral doses of IRL757 in healthy individuals aged 65 and older. It is expected to conclude in late-Q424.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.